Reproducibility of Ki67 Haralick entropy as a prognostic marker in estrogen receptor–positive HER2-negative breast cancer
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqaf081 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Dovile Zilenaite-Petrulaitiene und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digital Medicine, Translational Health Research Institute, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. Hauptthemen laut MEDLINE: Ki-67 Antigen, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Lithuania.
Abstract (Originalsprache)
Objective
Intratumoral heterogeneity (ITH) of Ki67 expression reflects the proliferative diversity of breast cancer (BC) cells and has been associated with disease progression. Quantification of Ki67 ITH using Haralick entropy metric from digital image analysis (DIA) has been reported as an independent predictor of breast cancer–specific survival (BCSS); however, its reproducibility across DIA platforms and dependence on tumor tissue sampling have not been investigated.
Methods
Whole-slide images of Ki67-stained tumor sections from 254 patients with ER+/HER2− BC were analyzed independently using HALO and Aiforia DIA platforms. The DIA outputs were subsampled using hexagonal grids to compute Ki67 Haralick entropy. Reproducibility was tested across DIA platforms and under simulated surgical excision and core biopsy scenarios. Lastly, the impact on prognostic modeling for BCSS was assessed.
Results
Haralick entropy demonstrated strong Ki67 ITH cross-platform reproducibility. For prognosis, it provided stronger model performance than conventional Ki67% metrics and independently predicted worse BCSS alongside lymph node involvement. Its prognostic value remained consistent across simulated sampling scenarios.
Conclusions
Ki67 Haralick entropy is a reproducible and robust image-derived ITH metric in ER+/HER2− BC. It demonstrated improved prognostic modeling performance compared to conventional Ki67% across 2 different DIA platforms and sampling conditions, supporting its potential for clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Digital Medicine, Translational Health Research Institute, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
- Department of Pathology and Forensic Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
- National Center of Pathology, affiliate of Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
- Institute of Computer Science, Faculty of Mathematics and Informatics, Vilnius University, Vilnius, Lithuania.
ORCID-Profile: Dovile Zilenaite-Petrulaitiene
Förderung
- Research Council of Lithuania
Zitieren
APA
Zilenaite-Petrulaitiene, D., Rasmusson, A., Valkiuniene, R. B., Laurinaviciene, A., Petkevicius, L., & Laurinavicius, A. (2025). Reproducibility of Ki67 Haralick entropy as a prognostic marker in estrogen receptor–positive HER2-negative breast cancer. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqaf081
Vancouver
Zilenaite-Petrulaitiene D, Rasmusson A, Valkiuniene RB, Laurinaviciene A, Petkevicius L, Laurinavicius A. Reproducibility of Ki67 Haralick entropy as a prognostic marker in estrogen receptor–positive HER2-negative breast cancer. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqaf081
BibTeX
@article{ZilenaitePetrulaitiene2025,
author = {Zilenaite-Petrulaitiene, Dovile and Rasmusson, Allan and Valkiuniene, Ruta Barbora and Laurinaviciene, Aida and Petkevicius, Linas and Laurinavicius, Arvydas},
title = {Reproducibility of Ki67 Haralick entropy as a prognostic marker in estrogen receptor–positive HER2-negative breast cancer},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqaf081}
}
EUVIMED